Bradykinin’s Modest Role in Sacubitril/Valsartan’s Blood Pressure Effects Revealed

Background

Heart failure with reduced ejection fraction (HFrEF) remains a significant clinical challenge, with symptomatic hypotension often limiting the use of effective therapies like sacubitril/valsartan. This study explores the mechanisms behind blood pressure reduction induced by sacubitril/valsartan, focusing on the role of bradykinin, a vasodilator potentially augmented by neprilysin inhibition.

Study Design

The study was a randomized, double-blind crossover trial involving stable ambulatory patients with HFrEF (ejection fraction <50%). Participants received intravenous icatibant, a bradykinin B2 receptor inhibitor, or placebo following sacubitril/valsartan dosing. Measurements included mean arterial pressure (MAP), plasma natriuretic peptides, urine cyclic GMP, and renal hemodynamics.

Key Findings

Initial dosing of sacubitril/valsartan reduced MAP by approximately 10 mm Hg, unaffected by icatibant, suggesting ANP’s primary role. After 8 weeks, icatibant attenuated MAP reduction (9 vs. 12 mm Hg; P=0.013), indicating bradykinin’s contribution during chronic therapy. Renal plasma flow decreased with icatibant, highlighting bradykinin’s vascular effects.

Expert Commentary

This study clarifies the temporal dynamics of sacubitril/valsartan’s effects, with ANP driving acute blood pressure changes and bradykinin playing a role in chronic therapy. These insights may guide clinical management to mitigate hypotension risks while optimizing therapeutic benefits.

Conclusion

The findings underscore the complex interplay of vasoactive peptides in sacubitril/valsartan’s mechanism, offering potential strategies to enhance tolerability and efficacy in HFrEF treatment.

Funding and ClinicalTrials.gov

Supported by [funding source], registered as NCT04113109 at ClinicalTrials.gov.